Targeted Diseases

Algernon Pharmaceuticals has developed data that supports the advancement of up to 11 drug candidates into phase II trials in the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD).